Related resources and publications
Tumor-graft models
Humanized PD-1/PD-L1 mouse and cell line
Front Immunol
PLoS One
Immunology
Our humanized & Knockout ICP cell lines can be used for in vivo tumor growth assays in syngeneic models and in vitro mechanistic studies.
Our humanized and Knockout immune checkpoint cell lines represent cutting-edge advancements in the field of immuno-oncology research. These meticulously engineered cell lines play a pivotal role in unraveling the complexities of immune responses and checkpoint regulation.
The Humanized cell lines are tailored to express human immune checkpoint proteins, providing a more accurate reflection of human immune system behavior.
On the other hand, the Knockout cell lines involve the targeted inactivation of specific immune checkpoint genes, allowing researchers to study the effects of these alterations on immune function.
These innovative cell lines serve as invaluable tools for exploring the intricate mechanisms of immune checkpoint pathways, paving the way for advancements in immunotherapy and contributing significantly to the development of novel therapeutic strategies.
The MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.
The MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1 and human HER2.
The Pd-l1 Knockout colon adenocarcinoma MC38 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.
The humanized PD-L1 syngeneic clonal colon carcinoma CT26 cell line expresses high levels of human PD-L1 and forms solid tumors in vivo.
The Pd-l1 Knockout colon carcinoma CT26 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.
CT26-hEpCAM-LZ clonal cell line expresses high levels of human EpCAM, and forms solid tumors in vivo.
The CT26-hCD39-LZ clonal cell line expresses high levels of human/mouse chimeric CD39, and forms solid tumors in vivo.
The MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form infiltrated tumors in immunocompetent mice.
Tumor-graft models
Humanized PD-1/PD-L1 mouse and cell line
Front Immunol
PLoS One
Immunology
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate